Biopharmaceutical classification of drugs using intrinsic dissolution rate (IDR) and rat intestinal permeability

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 73, Issue 1, 2009, Pages 102-106

  Zakeri Milani, Parvin ^a,b   Barzegar Jalali, Mohammad ^a,c   Azimi, Mandana ^d   Valizadeh, Hadi ^a,e  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Biopharmaceutics; Intestinal permeability; Intrinsic dissolution rate

Indexed keywords

ATENOLOL; CARBAMAZEPINE; CIMETIDINE; FUROSEMIDE; IBUPROFEN; KETOPROFEN; METOPROLOL; NAPROXEN; PHENAZONE; PIROXICAM; PROPRANOLOL; RANITIDINE; VERAPAMIL;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLASSIFICATION; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG SOLUBILITY; HUMAN; INTESTINE MUCOSA PERMEABILITY; JEJUNUM; MALE; MEASUREMENT; NONHUMAN; PERFUSION; RAT;

ANIMALS; BIOPHARMACEUTICS; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; MALE; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; RATS; RATS, WISTAR; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 68349157679     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2009.04.015     Document Type: Article

References (43)

1. Laihanen N., Muttonen E., and Laaksonen M. Solubility and intrinsic dissolution rate of alprazolam crystal modifications. Pharm. Dev. Technol. 1 (1996) 373-380
2. Dastmalchi S., Garjani A., Maleki N., Sheikhee G., Baghchevan V., Jafari-Azad P., Valizadeh H., and Barzegar-Jalali M. Enhancing dissolution, serum concentrations and hypoglycemic effect of glibenclamide using solvent deposition technique. J. Pharm. Pharm. Sci. 8 (2005) 175-181
3. Barzegar-Jalali M., Nayebi A.M., Valizadeh H., Hanaee J., Barzegar-Jalali A., Adibkia K., Anoush M., and Sistanizad M. Evaluation of in vitro-in vivo correlation and anticonvulsive effect of carbamazepine after cogrinding with microcrystalline cellulose. J. Pharm. Pharm. Sci. 9 (2006) 307-316
4. Barzegar-Jalali M., Valizadeh H., Dastmalchi S., Shadbad M.R.S., Barzegar-Jalali A., Adibkia K., and Mohammadi G. Enhancing dissolution rate of carbamazepine via cogrinding with crospovidone and hydroxypropylmethylcellulose. Iran. J. Pharm. Res. 6 (2007) 159-165
5. Valizadeh H., Nokhodchi A., Qarakhani N., Zakeri-Milani P., Azarmi S., Hassanzadeh D., and Lobenberg R. Physicochemical characterization of solid dispersions of indomethacin with PEG 6000, Myrj 52, lactose, sorbitol, dextrin, and Eudragit E100. Drug Dev. Ind. Pharm. 30 (2004) 303-317
6. Valizadeh H., Zakeri-Milani P., Barzegar-Jalali M., Mohammadi G., Danesh-Bahreini M.A., Adibkia K., and Nokhodchi A. Preparation and characterization of solid dispersions of piroxicam with hydrophilic carriers. Drug Dev. Ind. Pharm. 33 (2007) 45-56
7. Haleblian J., and McCrone W. Pharmaceutical applications of polymorphism. J. Pharm. Sci. 58 (1969) 911-929
8. Amidon G.E., Higuchi W.I., and Ho N.F. Theoretical and experimental studies of transport of micelle-solubilized solutes. J. Pharm. Sci. 71 (1982) 77-84
9. Yu L.X., Carlin A.S., Amidon G.L., and Hussain A.S. Feasibility studies of utilizing disk intrinsic dissolution rate to classify drugs. Int. J. Pharm. 270 (2004) 221-227
10. Jinno J., Oh D., Crison J.R., and Amidon G.L. Dissolution of ionizable water-insoluble drugs: the combined effect of pH and surfactant. J. Pharm. Sci. 89 (2000) 268-274
11. Dahlan R., McDonald C., and Sunderland V.B. Solubilities and intrinsic dissolution rates of sulphamethoxazole and trimethoprim. J. Pharm. Pharmacol. 39 (1987) 246-251
12. Levy G. Effect of certain tablet formulation factors on dissolution rate of the active ingredient. I. Importance of using appropriate agitation intensities for in vitro dissolution rate measurements to reflect in vivo conditions. J. Pharm. Sci. 52 (1963) 1039-1046
13. Nelson E. Comparative dissolution rates of weak acids and their sodium salts. J. Am. Pharm. Assoc. Am. Pharm. Assoc. (Baltim) 47 (1958) 297-299
14. Wood J., Syarto J., and Letterman H. Improved holder for intrinsic dissolution rate studies. J. Pharm. Sci. 54 (1965) 1068
15. Hillgren K.M., Kato A., and Borchardt R.T. In vitro systems for studying intestinal drug absorption. Med. Res. Rev. 15 (1995) 83-109
16. Zakeri-Milani P., Valizadeh H., Tajerzadeh H., Azarmi Y., Islambolchilar Z., Barzegar S., and Barzegar-Jalali M. Predicting human intestinal permeability using single-pass intestinal perfusion in rat. J. Pharm. Pharm. Sci. 10 (2007) 368-379
17. Sinko P.J., Hu P., Waclawski A.P., and Patel N.R. Oral absorption of anti-AIDS nucleoside analogues. 1. Intestinal transport of didanosine in rat and rabbit preparations. J. Pharm. Sci. 84 (1995) 959-965
18. Zakeri-Milani P., Valizadeh H., Yadollah Azarmi Y., Barzegar Jalali M., and Tajerzadeh H. Simultaneous determination of metoprolol, propranolol and phenol red in samples from rat in situ intestinal perfusion studies. DARU 14 (2006) 102-108
19. Zakeri-Milani P., Barzegar-Jalali M., Tajerzadeh H., Azarmi Y., and Valizadeh H. Simultaneous determination of naproxen, ketoprofen and phenol red in samples from rat intestinal permeability studies: HPLC method development and validation. J. Pharm. Biomed. Anal. 39 (2005) 624-630
20. Ernest D., Alfert E., Brenda M., Cross B.M., and McWilliam A.A.E. CCAC, guide to the care and use of experimental animals. Can. Council Animal Care 1 (1993) 1-150
21. Valizadeh H., Zakeri-Milani P., Islambulchilar Z., and Tajerzadeh H. A simple and rapid high-performance liquid chromatography method for determining furosemide, hydrochlorothiazide, and phenol red: applicability to intestinal permeability studies. J. AOAC Int. 89 (2006) 88-93
22. Gupta E., Barends D.M., Yamashita E., Lentz K.A., Harmsze A.M., Shah V.P., Dressman J.B., and Lipper R.A. Review of global regulations concerning biowaivers for immediate release solid oral dosage forms. Eur. J. Pharm. Sci. 29 (2006) 315-324
23. Granero G.E., Longhi M.R., Becker C., Junginger H.E., Kopp S., Midha K.K., Shah V.P., Stavchansky S., Dressman J.B., and Barends D.M. Biowaiver monographs for immediate release solid oral dosage forms: acetazolamide. J. Pharm. Sci. 97 (2008) 3691-3699
24. Kortejarvi H., Yliperttula M., Dressman J.B., Junginger H.E., Midha K.K., Shah V.P., and Barends D.M. Biowaiver monographs for immediate release solid oral dosage forms: ranitidine hydrochloride. J. Pharm. Sci. 94 (2005) 1617-1625
25. Nicklasson M., Brodin A., and Graffner C. Studies on a rotating disk method to determine drug dissolution rates from inert PVC matrices. Acta Pharm. Suec. 19 (1982) 211-222
26. Amidon G.L., Lennernas H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413-420
27. P. Parvin Zakeri-Milani, H. Valizadeh, H. Tajerzadeh, Z. Islambolchilar, The utility of rat jejunal permeability values for biopharmaceutics classification system, Drug Dev. Ind. Pharm., (2009), in press.
28. Kasim N.A., Whitehouse M., Ramachandran C., Bermejo M., Lennernas H., Hussain A.S., Junginger H.E., Stavchansky S.A., Midha K.K., Shah V.P., and Amidon G.L. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol. Pharm. 1 (2003) 85-96
29. WHO, Multisource (Generic) Pharmaceutical Products: Guidelines on Registration Requirements to Establish Interchangeability. Technical Report Series, No937, 40th Report, Annex7 , 2006.
30. FDA, Guidance for Industry: Waiver of in vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. US Food and Drug Administration, Center for Drug Evaluation and Research, USA, , 2000.
31. EMEA, Note for Guidance on the Investigation of Bioavailability and Bioequivalence. European Agency for Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products, ., 2001.
32. Yu L.X., Amidon G.L., Polli J.E., Zhao H., Mehta M.U., Conner D.P., Shah V.P., Lesko L.J., Chen M.L., Lee V.H., and Hussain A.S. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm. Res. 19 (2002) 921-925
33. Takagi T., Ramachandran C., Bermejo M., Yamashita S., Yu L.X., and Amidon G.L. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol. Pharm. 3 (2006) 631-643
34. Benet L.Z., Amidon G.L., Barends D.M., Lennernas H., Polli J.E., Shah V.P., Stavchansky S.A., and Yu L.X. The use of BDDCS in classifying the permeability of marketed drugs. Pharm. Res. 25 (2008) 483-488
35. Wu C.Y., and Benet L.Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22 (2005) 11-23
36. Papadopoulou V., Valsami G., Dokoumetzidis A., and Macheras P. Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): theoretical basis and practical examples. Int. J. Pharm. 361 (2008) 70-77
37. Lennernas H. Human intestinal permeability. J. Pharm. Sci. 87 (1998) 403-410
38. Modamio P., Lastra C.F., and Maritto J. Error structure for the HPLC analysis for atenolol, metoprolol and propranolol: a useful weighting method in parameter estimation. J. Pharm. Biomed. Anal. 17 (1998) 507-513
39. Irvine J.D., Takahashi L., Lockhart K., Cheong J., Tolan J.W., Selick H.E., and Grove J.R. MDCK cells: a tool for membrane permeability screening. J. Pharm. Sci. 88 (1998) 28-33
40. Phillips C.A., and Michniak B.B. Transdermal delivery of drugs with differing lipophilicities using azone analogs as dermal penetration enhancers. J. Pharm. Sci. 84 (1995) 1427-1433
41. Walker E., janich S., Roessler B.J., Hilfinger J.M., and Amidon G.L. HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro- in vivo correlation with permeability data from rats and humans. J. Pharm. Sci. 85 (1996) 1070-1076
42. Levitt M.D., Kneip J.M., and Levitt D.G. Use of laminar flow and unstirred layer models to predict intestinal absorption in the rat. J. Clin. Invest. 81 (1988) 1365-1369
43. Lennernäs H., Knutson L., Hussain A., Lesko L., Salmonson T., and Amidon G. The human jejunal Peff-value for each enantiomet of (R,S)-verapamil. Pharm. Res. 13 (1996) 246